Lupin receives approval from U.S. FDA for Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml

Global pharma major Lupin Limited (Lupin) has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml, Unit-dose Vials to market a generic equivalent of Brovana ® Inhalation Solution, 15 mcg /2 ml of Sunovion Pharmaceuticals Inc. (Sunovion).

Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml, Unit-dose Vials are indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Arformoterol Tartrate Inhalation Solution is for use by nebulization only.

Arformoterol Tartrate Inhalation Solution (RLD: Brovanas Inhalation Solution) had estimated annual sales of USD 251 million in the U.S. (IQVIA MAT December 2021).

Shares of Lupin Limited was last trading in BSE at Rs. 787.80 as compared to the previous close of Rs. 804.45. The total number of shares traded during the day was 108920 in over 5557 trades.

The stock hit an intraday high of Rs. 810.45 and intraday low of 784.60. The net turnover during the day was Rs. 86502173.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA ANDAApproval ArfomoterolTartrate Sunovion